Table 2. Dominant lethal assay (DLA) after males were treated with Zidovudine or Nevirapine for eight weeks.
| Drug | Dose (mg/kg) | Sample size (n) | aPregnant (n) | DLA Implants (n) | |||||
| cSize | Dead | Resorbed | |||||||
| None | None | 6 | 4 | 6.8 | 0 | 1.0 | |||
| EMS | 480 | 6 | 2 | 8.0 | 0 | 8.0 | |||
| ZDV | d10 | 6 | b2/4 | 6.0 | 0 | 0 | |||
| d100 | 6 | b3/4 | 8.3 | 1.0 | 1.0 | ||||
| 250 | 6 | 3 | 9.0 | 0 | 4.0 | ||||
| NVP | 5 | 6 | b0/2 | - | - | - | |||
| 50 | 6 | b0/2 | - | - | - | ||||
| 150 | 6 | b0/3 | - | - | - | ||||
DLA simulates when the “father-only” is ARV treated.
EMS = Ethylmethylsulfonate (one-time dose); ZDV = Zidovudine; NVP = Nevirapine.
a
Number of pregnancies observed after 1∶1 mating.
b
Number of pregnancies before/after adding dams with heavy arterial linings to the pregnancy count. Dams with heavy arterial lining of the uterus and/or uterine fluids indicate fertile mating had occurred but was aborted early.
c
Number of implants per pregnant dam or the average from all pregnant dams in the group.
Differences in number of aborted pregnancies at week 4 versus week 8 was not significant.